Oncology is the largest single therapeutic area in biotech hiring — and the most competitive. Recruits Lab runs oncology searches with recruiters who know the mechanism landscape, competitive pipeline, and clinical trial design realities that a generalist recruiter cannot hold at depth.
Oncology is the largest, most crowded, and most competitive hiring market in biotech. The volume of programs across solid tumor, hematologic malignancies, and immuno-oncology far exceeds the supply of senior leaders who have actually run successful trials. The cost of a wrong oncology hire is rarely the recruiting fee — it is the program that loses 6 to 12 months of competitive position.
Recruits Lab places oncology talent for venture-backed biotech and specialty pharma across discovery oncology, translational oncology, clinical oncology, and commercial oncology. Our practice spans Scientist through Director, VP, and CMO levels with deep specialization by tumor type, modality, and trial phase.
Our recruiters understand the distinctions that matter — solid tumor scientists who have actually contributed to clinical-stage programs versus those who have only done early discovery, IO leaders with real combination experience versus mono-therapy backgrounds, and clinical oncology MDs with pivotal trial leadership versus support roles. We screen for ownership and depth.
Most oncology searches at venture-backed companies struggle because the role demands both deep oncology expertise and venture-backed pace. Big pharma oncology talent is the largest pool, but the transition requires cultural calibration. We screen for it directly.
Subscription pricing is what makes specialized oncology search affordable for venture-backed teams. The economics free hiring leaders to make the right hire rather than the cheapest one to source.
Why this market is hard to recruit for. And how we solve each one.
Solid tumor and hematologic oncology are distinct worlds. Within solid, lung and GI and breast are distinct. We map candidates to your tumor type.
Antibody, ADC, bispecific, cell therapy, and small molecule oncology programs each demand different expertise. We screen for the right match.
True pivotal trial ownership is rarer than resumes suggest. We screen for direct experience.
Big pharma oncology talent often struggles with venture-backed velocity. We screen for the cultural shift.
IO combinations require specific experience. We screen for it directly.
Senior oncology talent is courted constantly. We manage offer and resign conversations.
The repeatable system behind our 14-day average hire time.
We run a deep intake call with hiring managers and scientific leadership covering technical must-haves, dealbreakers, comp band, equity philosophy, and the cultural traits that predict success in your specific stage and program.
We build a fresh map of 80-150 qualified candidates from direct competitors, academic spinouts, CROs, and adjacent therapeutic areas. No database scraping — real research from a recruiter who understands the science.
Personalized outreach from a senior recruiter who can actually discuss your molecule, mechanism, or modality. Response rates run 3-5x higher than generalist agencies because the first message reads like it came from another scientist.
Five to eight vetted candidates with structured profile briefs covering technical fit, motivation, publication record where relevant, comp expectations, and risk factors. Not a resume dump — a decision document.
We manage offer construction, counter-offer scenarios, resign coaching, and start-date negotiation. Every placement carries a 90-day replacement guarantee at no additional fee.
Original observations from live searches in this specialty.
An oncology scientist with ADC depth is not an oncology scientist with IO depth. The mechanism-class pools are separate at the senior tier. We source specifically for the mechanism your program is built on rather than from a generalist oncology pool.
Clinical Directors and Medical Directors in oncology at venture-backed biotech routinely receive pharma counter-offers 30-50 percent above their current comp. We surface this reality in intake and pre-negotiate offer construction to hold the close.
In 2026, oncology Director hires are increasingly filtered on whether the candidate can hold a real conversation about patient selection biomarkers. Candidates who cannot are limited to programs without an enrichment strategy — a shrinking share of the oncology pipeline.
2026 U.S. base salary ranges for oncology roles at venture-backed and mid-cap life sciences companies. Excludes equity, bonus, and sign-on. Ranges reflect Series A through commercial-stage benchmarks.
| Role | Base Salary Range |
|---|---|
| Senior Scientist, Oncology | $160K–$215K |
| Principal Scientist, Oncology | $190K–$250K |
| Director, Translational Oncology | $250K–$320K |
| Medical Director, Oncology | $320K–$415K |
| Senior Director, Clinical Oncology | $360K–$465K |
| VP, Clinical Development (Oncology) | $420K–$540K |
| Chief Medical Officer, Oncology | $475K–$650K |
Source: Recruits Lab 2026 Life Sciences Compensation dataset.
Quick answers to the questions founders and hiring leaders ask most.
Oncology recruiters source, screen, and qualify scientists, MDs, and clinical leaders across solid tumor, hematologic, and immuno-oncology programs. Recruits Lab specializes in oncology and averages 14 days from kickoff to offer.
Industry average for VP and CMO-level oncology is 120 to 200 days. Recruits Lab averages 14 days.
Yes. Medical Directors, Senior Medical Directors, and CMOs in oncology are core practice.
Subscription starts at $7,500 per month with unlimited active roles. Contingency is a flat 20 percent with a 90-day guarantee.
Yes. ADC and bispecific oncology are growing parts of the practice.
Medical Director, Oncology with combination IO trial leadership needed ahead of pivotal trial start. Two retained firms had failed across eight months.
Mapped 18 combination IO clinical leads nationally. Senior recruiter ran outbound, presented a four-person shortlist in 14 days.
Offer accepted in 25 days. Pivotal trial launched on the original timeline.
"Recruits Lab understood the science from day one. They sent four interview-ready candidates inside two weeks after our internal team had spent three months on the role."
"Their subscription model let us close three scientific hires in a single quarter for less than what a single retained search would have cost us."
Yes. Heme oncology is a core practice area including MM, AML, and lymphoma programs.
Yes. CAR-T and TCR-T programs are part of the oncology practice.
Yes. Commercial oncology leadership is an adjacent practice area.
Yes. Rare and pediatric oncology are part of the practice.
Yes. Multi-hire clinical oncology builds ahead of pivotal trials are routine engagements.
Every placement carries a 90-day replacement guarantee. If a hire leaves or does not work out within the first 90 days, we run the search again at no additional fee.
Yes. We sign NDAs and routinely run confidential and stealth-mode searches for executive replacements, sensitive program leads, and pre-launch hires.
Book a free 30-minute hiring strategy review using the CTA on this page. We will scope the role, suggest a sourcing approach, and quote a subscription or contingency option that fits your stage.
Compensation data, hiring playbooks, case studies, and related recruiting specialties.
Four ways to engage. Pick whichever matches where you are.
30-minute strategy review with a senior recruiter. Free, no commitment.
Get startedTell us about the role. We respond with a calibration call within 24 hours.
Get startedSend a job description. We confirm fit and quote a subscription or contingency engagement.
Get startedSenior candidates: get represented to our active hiring pipeline.
Get startedRelated Resources
Hand-picked salary guides, market reports, and recruiter pages related to this topic. Authored by Darren Nelson and the Recruits Lab team.
Schedule a free 30-minute Hiring Strategy Review and walk away with a clear plan tailored to your roles.